Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pneumococcal Infections: later-stage trial registry
A small indexed set (11 trials) with no open enrollment listed right now.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · none currently recruiting · #1,577 of 28,707 conditions by registered trial count
Pneumococcal Infections: 11 US clinical trials tracked, none currently recruiting.
Pneumococcal Infections is the subject of 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 7 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Merck Sharp & Dohme, running 6 of these trials.
Enrollment posture brief
Registry condition pneumococcal-infections
OPEN 0 | RECR 0% | LATE 7 | EARLY 2 | RANK #1577 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Pneumococcal Infections has no open enrollment in this registry pull (11 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pneumococcal Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pneumococcal Infections is recruiting below its size-band peers.
0 of 11 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pneumococcal Infections research.
Merck Sharp & Dohme accounts for 6 of 11 trials (54.5%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Pneumococcal Infections enrolment sits around 938 participants.
Median target enrolment is 938 among the 11 trials that report a genuine target (sentinel values excluded). 1 of those (9.1%) plan for fewer than 100 participants.
-
Pneumococcal Infections research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
11 total, page 1 of 1
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
Sanofi Pasteur, a Sanofi Company
NCT06838000
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
Merck Sharp & Dohme
NCT03547167
Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)
Merck Sharp & Dohme
NCT03950622
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
Merck Sharp & Dohme
NCT03615482
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
Merck Sharp & Dohme
NCT02987972
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00546572
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
Merck Sharp & Dohme
NCT03620162
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000933
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00013871
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
Merck Sharp & Dohme
NCT03565900
A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
Pfizer
NCT02955160
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Pneumococcal Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pneumococcal Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pneumococcal Infections page
11 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Pneumococcal Infections trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Merck Sharp & Dohme sponsors the most Pneumococcal Infections trials on record, review their full trial history before evaluating a specific study. See Merck Sharp & Dohme's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pneumococcal Infections condition card totals 11 registered trials; most-linked intervention V114; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.